Venlafaxine: a novel antidepressant that has a dual mechanism of action.
about
Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers.Efficacy of venlafaxine in the treatment of severe depression.A case of venlafaxine-induced interstitial lung disease.Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma.New concepts in the drug therapy of Alzheimer's disease.Chiral determination of antidepressant drugs and their metabolites in biological samples.Natural polyphenols in the management of major depression.Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.IFN-gamma reduction by tricyclic antidepressants.Nonaqueous capillary electrophoresis-mass spectrometry for separation of venlafaxine and its phase I metabolites.On-line capillary electrophoresis-electrospray mass spectrometry for the stereoselective analysis of drugs and metabolites.Synthesis of new 1-phenyl-2-(4-substituted-piperazin-1-yl)-propanol derivatives and evaluation of their antidepressant-like effects.Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine.Biochemical effects of venlafaxine on astrocytes as revealed by 1H NMR-based metabolic profiling.Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake.Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study.Establishing bioequivalence of racemic venlafaxine formulations using stereoselective assay method: Is it necessary?
P2860
Q33820745-AB754D88-0ABF-4DFA-B441-F6B14139FD46Q34093702-EB934C67-FC32-4AEC-BE54-035E45D26C40Q34195026-A11D5B9C-C053-479D-958C-C9ECCAA44FA3Q34481741-BBCD7513-0682-4DA4-8EE0-6CDB0F24E7DBQ34515565-638E59C8-61CA-4FFF-8D51-81D1AED614D3Q37810213-4E26B08C-B1C5-4C97-9144-A829C3EA388FQ38103949-8C34BA82-1553-461E-A9EE-49A40689B00FQ40955809-E4821846-AE22-4E44-B942-500017C3B7D7Q42746526-353C3EC4-2E73-4E57-AD30-A68EE63E0FF5Q43547499-9C278DAB-B6CE-43F8-85B3-F0FD65105BD9Q43758339-CC94046B-F2C9-4391-B17D-CBA08DE96D2DQ45903384-AA09CFCD-371D-4516-8F33-90CC1C17985EQ47834595-CC80EC08-2604-474B-856F-92C5FB3B49F1Q48001597-B371055C-76E8-4290-BAC3-95E8A650AC5DQ48348353-BD4A459B-BD77-4D6E-B3C2-D72311E67016Q48826911-930C9796-9055-4B13-9C67-8BDBF1807A5EQ49670994-A068DA6D-CE26-4541-9816-310155EC794FQ51367505-7DCA6612-9C69-4123-961C-FE91EBCF5D7C
P2860
Venlafaxine: a novel antidepressant that has a dual mechanism of action.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Venlafaxine: a novel antidepressant that has a dual mechanism of action.
@en
type
label
Venlafaxine: a novel antidepressant that has a dual mechanism of action.
@en
prefLabel
Venlafaxine: a novel antidepressant that has a dual mechanism of action.
@en
P2093
P1433
P1476
Venlafaxine: a novel antidepressant that has a dual mechanism of action.
@en
P2093
P356
10.1002/(SICI)1522-7162(1996)4:2<48::AID-DEPR2>3.0.CO;2-B
P577
1996-01-01T00:00:00Z